论文信息 - Second act

Second act

In February 2011, the British drug company AstraZeneca shelved its experimental drug zibotentan, intended for the treatment of nonmetastatic prostate cancer in men who do not respond to hormonal treatments. Despite early promise, the drug failed to improve patients’ survival in trials. But more than a year later, the drug might get a second wind, this time as a potential treatment for Alzheimer’s disease, thanks to a partnership between industry and academia. With AstraZeneca crowdsourcing the search for potential new applications for its drugs in the academic community, the partnership could lead to treatments not apparent during the original development of the drug.

Prashant Nair | P. Nair

[1] Alexander A. Morgan,et al. Discovery and Preclinical Validation of Drug Indications Using Compendia of Public Gene Expression Data , 2011, Science Translational Medicine.

[2] Joel Dudley,et al. Exploiting drug-disease relationships for computational drug repositioning , 2011, Briefings Bioinform..

[3] S. Love,et al. Endothelin-1 is elevated in Alzheimer's disease and upregulated by amyloid-β. , 2012, Journal of Alzheimer's disease : JAD.

[4] Paul A Clemons,et al. The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[5] David Baker,et al. Algorithm discovery by protein folding game players , 2011, Proceedings of the National Academy of Sciences.

[6] Alexander A. Morgan,et al. Computational Repositioning of the Anticonvulsant Topiramate for Inflammatory Bowel Disease , 2011, Science Translational Medicine.